Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type … Read more
Corcept Therapeutics Incorporated - Asset Resilience Ratio
Corcept Therapeutics Incorporated (CORT) has an Asset Resilience Ratio of 30.08% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how Corcept Therapeutics Incorporated's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Corcept Therapeutics Incorporated's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $251.66 Million | 30.08% |
| Total Liquid Assets | $251.66 Million | 30.08% |
Asset Resilience Insights
- Very High Liquidity: Corcept Therapeutics Incorporated maintains exceptional liquid asset reserves at 30.08% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Corcept Therapeutics Incorporated Industry Peers by Asset Resilience Ratio
Compare Corcept Therapeutics Incorporated's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Corcept Therapeutics Incorporated (2002–2025)
The table below shows the annual Asset Resilience Ratio data for Corcept Therapeutics Incorporated.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 30.08% | $251.66 Million | $836.65 Million | -0.34pp |
| 2024-12-31 | 30.42% | $255.67 Million | $840.55 Million | -7.02pp |
| 2023-12-31 | 37.44% | $232.67 Million | $621.52 Million | -25.18pp |
| 2022-12-31 | 62.62% | $365.34 Million | $583.43 Million | +28.19pp |
| 2021-12-31 | 34.43% | $145.92 Million | $423.76 Million | -29.32pp |
| 2020-12-31 | 63.75% | $364.51 Million | $571.73 Million | +4.41pp |
| 2019-12-31 | 59.35% | $244.69 Million | $412.31 Million | +6.37pp |
| 2018-12-31 | 52.98% | $165.13 Million | $311.69 Million | +26.82pp |
| 2017-12-31 | 26.16% | $57.68 Million | $220.54 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $68.75 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $51.94 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $34.63 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $63.08 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $99.17 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $39.83 Million | -- |
| 2008-12-31 | 18.17% | $3.59 Million | $19.77 Million | -15.27pp |
| 2007-12-31 | 33.44% | $5.93 Million | $17.74 Million | +27.88pp |
| 2006-12-31 | 5.55% | $550.00K | $9.90 Million | -78.22pp |
| 2005-12-31 | 83.78% | $25.26 Million | $30.16 Million | +17.90pp |
| 2004-12-31 | 65.88% | $31.47 Million | $47.77 Million | +53.11pp |
| 2003-12-31 | 12.77% | $1.50 Million | $11.78 Million | -1.65pp |
| 2002-12-31 | 14.42% | $3.14 Million | $21.80 Million | -- |